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1118 | Med. Chem. Commun., 2013,Synthesis and biological evaluation of novel 2,3-
dihydro-1H-1,5-benzodiazepin-2-ones; potential
imaging agents of the metabotropic glutamate 2
receptor†
Lynne Gilﬁllan,a Adele Blair,a Brian J. Morris,b Judith A. Pratt,c Lutz Schweiger,d
Sally Pimlotte and Andrew Sutherland*a
A focused library of novel 2,3-dihydro-1H-1,5-benzodiazepin-2-ones containing sites for 11C-, 18F- and 123I-
labelling have been prepared and evaluated against membrane expressing human recombinant
metabotropic glutamate 2 receptor (mGluR2). The compounds were found to be non-competitive
antagonists with nanomolar aﬃnity. HPLC evaluation of the physiochemical properties of these
compounds identiﬁed two candidates for PET and SPECT imaging of mGluR2.Introduction
Metabotropic glutamate receptors (mGluR) are a superfamily of
G-protein coupled receptors found embedded within cell
membranes. In the central nervous system (CNS), they modu-
late L-glutamate neurotransmission and are also considered to
aﬀect dopaminergic and adrenergic neurotransmission.1 Eight
members of the family of mGluRs (1–8) have been cloned and
are separated into three groups based on their signal induction
pathway and sequence homology.2 Group 1 receptors (mGluR1
and 5) are positively coupled to the activity of phospholipase C,
whereas group II (mGluR2 and 3) and group III (mGluR4 and
6–8) receptors which have a diﬀerent pharmacology, are both
negatively coupled to the activity of adenyl cyclase.3
The development of pharmacological agents targeting the
mGluRs has been recognised as a possible approach for the
treatment of various CNS disorders such as depression, anxiety
and schizophrenia.4 More specically, mGluR2/3 agonists have
been shown to exhibit anxiolytic and antipsychotic propertiesh Black Building, University of Glasgow,
utherland@glasgow.ac.uk; Fax: +44 (0)
niversity of Glasgow, Glasgow, G12 8QQ,
te of Pharmacy and Biomedical Sciences,
UK
of Medicine and Dentistry, University of
, UK
University of Glasgow and North Glasgow
1 6NT, UK
SI) available: Experimental procedures,
hesised, details of biological evaluation
ctra for all new compounds. See DOI:
4, 1118–1123while mGluR2/3 antagonists may be useful as anti-depressants
and cognitive enhancers.4b,5,6 Recently, Woltering and co-workers
initiated a programme of research to nd new mGluR2/3 ligands
with increased receptor selectivity and improved physiochemical
properties.7 Through a random screening programme, a library
of compounds based on a 2,3-dihydro-1H-1,5-benzodiazepin-2-
one core 1 (Fig. 1) were identied that showed excellent aﬃnity as
non-competitive antagonists when tested against rat mGluR2
receptors. Themost potent series of compounds contained 5- andFig. 1 2,3-Dihydro-1H-1,5-benzodiazepin-2-one derivatives.
This journal is ª The Royal Society of Chemistry 2013
Scheme 2 Reagents and conditions: (a) NH3, 1,4-dioxane, 100 C, 76%; (b)
MeOH, KOH, DMSO, 60 C, 97%; (c) 3-ﬂuoropropan-1-ol, K2CO3, DMSO, 120 C,
71%; (d) Boc2O (2.2 eq.), Et3N, DMAP (0.2 eq.), CH2Cl2, 95% (R¼Me), 82% (R¼ 3-
F-propyl); (e) TFA, CH2Cl2, 16 (100%), 17 (98%).
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View Article Online6-membered heterocyclic motifs such as 1-imidazoles, 1,2,3-tri-
azoles and 4-pyridines at the 30-position (R3).
We have a longstanding interest in developing molecular
tracers for positron emission tomography (PET) and single
photon emission computed tomography (SPECT) imaging of
neurological receptor targets.8 Based on the 30-imidazole derived
2,3-dihydro-1H-1,5-benzodiazepin-2-ones identied by the Wol-
tering group, we proposed to discover novel candidates that could
be used for PET and SPECT imaging of mGluR2 in schizophrenia.
Such compounds would have the potential to be used for the
diagnosis of schizophrenia as well as in the evaluation of new
drugs and in the measurement of treatment response.
Herein, we report our studies on the design and synthesis of
novel 30-imidazole derived 2,3-dihydro-1H-1,5-benzodiazepin-2-
ones bearing an iodophenyl moiety (2, 3) for SPECT imaging or
methyl and uoro groups (4, 5) for PET imaging as well as a
compound with multiple labelling sites (6) which could be used
for either modality (Fig. 1). We also report the biological
assessment of these compounds against membrane expressing
human recombinant mGluR2 as well as their suitability as
neurological imaging agents by the evaluation of their physi-
ochemical properties.Results and discussion
We began our studies with the synthesis of 3- and 4-iodophenyl
derivatives for application in SPECT imaging. Our general
strategy involved the preparation of selectively protected 1,2-
diaminobenzenes which could be coupled and cyclised with a
b-keto ester to generate the 2,3-dihydro-1H-1,5-benzodiazepin-
2-one core. Iodination would then be incorporated at the last
stage allowing this step to be modied for eventual radio-
iodination. As such, 2-nitroaniline (7) was iodinated regiose-
lectively using iodine monochloride9 and this was converted to
Boc-protected derivative 9 using a two-step strategy involving di-
protection,10 followed by selective removal of one of the Boc-
protecting groups (Scheme 1). This approach was found to be
more eﬃcient for all 1,2-diaminobenzenes prepared during this
study rather than direct mono-Boc protection of the aniline. A
palladium(0)-mediated Suzuki–Miyaura reaction under stan-
dard conditions with 3- or 4-bromophenylboronic acid andScheme 1 Reagents and conditions: (a) ICl, NaOAc, AcOH, 90 C, 88%; (b) Boc2O
(2.2 eq.), Et3N, DMAP (0.2 eq.), CH2Cl2, 70%; (c) TFA, CH2Cl2, 98%; (d) 3- or 4-I-
PhB(OH)2, (Ph3P)4Pd (2 mol%), K2CO3, DMF–H2O, 10 (72%), 11 (78%).
This journal is ª The Royal Society of Chemistry 2013using potassium carbonate as the base gave the corresponding
bi-phenyl derivatives 10 and 11 in good overall yields.
The aromatic core for the generation of the potential PET
tracers was prepared as shown in Scheme 2. 1,5-Dichloro-2-
nitro-4-(triuoromethyl)benzene (12) was selectively aminated
with ammonia to give 13 in good yield.11 Introduction of the
potential PET labels by nucleophilic aromatic substitution of 13
with either methanol or 3-uoropropan-1-ol gave alkoxy deriv-
atives 14 and 15. Application of the two-step approach for Boc-
protection of the anilines then gave compounds 16 and 17.
The nal compound prepared in this series required both an
iodophenyl group and methoxy moiety for application in either
SPECT or PET imaging, respectively. The 1,2-diaminobenzene
core was initially prepared from 2-nitro-5-chloroaniline (18)
which was subjected to a regioselective iodination with iodine
monochloride (Scheme 3). Nucleophilic aromatic substitution
at the 5-position with methanol allowed introduction of the
methoxy group in excellent yield. The two-step Boc-protection
sequence was then employed to give 21 and this was followed by
a Suzuki–Miyaura reaction with 4-bromophenylboronic acid to
give functionalised biphenyl 22 in good yield over the ve steps.
The nal stage of the synthesis of the selectively protected 1,2-
diaminobenzenes required the reduction of the 2-nitro group. As
several of these compounds (10, 11 and 22) contained labileScheme 3 Reagents and conditions: (a) ICl, NaOAc, AcOH, 80 C, 92%; (b)
MeOH, KOH, DMSO, 60 C, 94%; (c) Boc2O (2.2 eq.), Et3N, DMAP (0.2 eq.), CH2Cl2,
96%; (d) TFA, CH2Cl2, 100%; (e) 4-I-PhB(OH)2, (Ph3P)4Pd (2 mol%), K2CO3, DMF–
H2O, 66%.
Med. Chem. Commun., 2013, 4, 1118–1123 | 1119
Scheme 4 Reagents and conditions: (a) SnCl2$2H2O, EtOAc/pyridine, 23 (91%),
24 (72%), 25 (63%), 26 (85%), 27 (83%), 28 (75%); (b) 40% glyoxyl, MeOH then
NH4Cl, CH2O, H3PO4, 58%; (c) t-BuOAc, LiHMDS, THF, 80%; (d) D, toluene; (e) TFA,
CH2Cl2, yields over two steps: 31 (39%), 32 (55%), 33 (66%), 4 (48%), 5 (72%), 34
(69%).
Fig. 2 Graphs of control experiments with membrane expressing human
mGluR2, at: (a) 100 mM L-glutamate and (b) 10 mM L-glutamate (DPM ¼ disinte-
grations per minute).
Scheme 5 Reagents and conditions: (a) (Me3Sn)2, (Ph3P)4Pd (10 mol%), 1,4-
dioxane, 90 C; (b) NaI, chloramine-T, EtOH, 2 (69%), 3 (42%), 6 (47%).
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View Article Onlinecarbon–bromine bonds, a mild procedure was required. Initial
attempts using transfer hydrogenation with ammonium formate
led to reduction of both the bromide and nitro groups. However,
a successful transformation was identied using tin(II) chloride
dihydrate which led to the reduction of 9–11, 16, 17 and 22 under
basic conditions in generally high yields (Scheme 4).12 The b-keto
ester fragment 30 required for coupling with the 1,2-dia-
minobenzenes to generate the 2,3-dihydro-1H-1,5-benzodiaze-
pin-2-ones was prepared using a two stage approach. Methyl
3-(10H-imidazol-10-yl)benzoate was initially synthesised from
methyl 3-aminobenzoate (29) using an imidazole ring synthesis
described by Zhang and co-workers.13 Claisen condensation with
tert-butyl acetate gave 30 in 80% yield.14 Coupling of 30 with the
1,2-diaminobenzenes was performed under reux to give the
corresponding b-ketoamides.7 Subsequent treatment with TFA to
remove the Boc-protecting group and facilitate cyclisation led to
the isolation of the 2,3-dihydro-1H-1,5-benzodiazepin-2-ones in
good yields over the two steps.
The nal stage of the synthesis of the SPECT compounds
involved the iodination of the bromophenyl groups. Initial
attempts using a direct copper catalysed halogen exchange
reaction resulted in only isomerisation of the cyclic imine to the
corresponding enamine.15 Instead, a palladium(0)-mediated1120 | Med. Chem. Commun., 2013, 4, 1118–1123stannylation of the bromides with hexamethylditin was fol-
lowed by an oxidative iododestannylation and this gave the
target iodides, 2, 3 and 6 cleanly, in good yields over the two
steps (Scheme 5).
With the series of 2,3-dihydro-1H-1,5-benzodiazepin-2-ones
in hand, a functional [35S]GTPgS assay using membrane
expressing human mGluR2 was optimised.16 The [35S]GTPgS
assay is commonly used to determine binding to G-protein
coupled receptors in vitro. On stimulation of the receptor, in
this case mGluR2, with an agonist such as L-glutamate, [35S]-
guanosine 50-(g-thio)triphosphate ([35S]GTPgS) binds irrevers-
ibly to the Ga subunit of the G-protein. This accumulation of
[35S]GTPgS can be quantied by liquid scintillation analysis.
Addition of a non-competitive antagonist disrupts binding of
the agonist and thus, lowers accumulation of the [35S]GTPgS.
Before biological testing of the 2,3-dihydro-1H-1,5-benzo-
diazepin-2-ones, control experiments were performed toThis journal is ª The Royal Society of Chemistry 2013
Table 2 Physiochemical values
Compound log Pa Pm
b Km
b %PPBc
31 4.60 0.51 218.40 94.92
2 5.73 >2.27 >1144.81 98.46
3 5.77 >2.27 >1144.81 98.67
4 4.67 0.44 176.15 92.41
5 5.06 0.77 343.73 95.12
6 5.72 >2.13 >1138.17 98.32
a Determined using C18 column.
b Determined using immobilised
articial membrane (IAM) column. c Determined using human serum
albumin (HSA) coated column.
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View Article Onlineoptimise the assay. Initially, addition of [35S]GTPgS and
guanosine diphosphate to the membrane showed the expected
basal binding (Fig. 2a). Stimulation with 100 mM L-glutamate
resulted in a 117% increase over basal binding. Next, addition
of the known competitive antagonist LY341495 (10 mM) showed
the expected reduction of binding back to basal level.17 To gauge
the level of non-specic binding of [35S]GTPgS, the assay was
repeated with the addition of 10 mM [32S]GTPgS. This conrmed
the high specicity of [35S]GTPgS for the G-protein. Finally, a
further series of experiments using only 10 mM L-glutamate
showed a similar level of stimulation (95%) and therefore, thisTable 1 Inhibition of membrane expressing human recombinant mGluR2 by
2,3-dihydro-1H-1,5-benzodiazepin-2-ones
Compound IC50
a (nM)
533  27
89  5
132  7
133  24
91  30
100  14
89  46
a IC50 values are the mean  SD of three independent experiments
except for compounds 3 and 6, where n ¼ 2.19
This journal is ª The Royal Society of Chemistry 2013concentration was used during the biological evaluation of the
2,3-dihydro-1H-1,5-benzodiazepin-2-ones (Fig. 2b).
As a standard, commercially available Ro 64-5229 35, a
known selective non-competitive mGluR2 antagonist was
initially tested using the assay described above. This produced
an IC50 value (533 nM) of similar magnitude to that previously
reported for 35 when tested against rat mGluR2 transfected cell
membranes (Table 1).18 The series of 2,3-dihydro-1H-1,5-ben-
zodiazepin-2-ones were then evaluated. As can be observed for
Table 1, all of the compounds showed excellent aﬃnity for
mGluR2 with IC50 values ranging from 89 to 133 nM. In
particular, the sterically less-encumbered compounds 31 and 4
showed six times more potency than the standard, non-
competitive antagonist, Ro 64-5229 35.19
Selecting potential candidates as neurological imaging agents
for further development requires determination of a range of
physiochemical properties. For the compound to transverse brain
capillary endothelial cells and penetrate the blood brain barrier,
permeability across the plasma membrane is important.
Furthermore, for compounds which mainly transport across cell
membranes through passive diﬀusion, determining the
membrane partition coeﬃcient is crucial for successful develop-
ment. Based on a recently reported study of HPLC methods for
determining these key physiochemical properties of imaging
agents,20 the partition coeﬃcient (log P), permeability (Pm), the
membrane partition coeﬃcient (Km) and the percentage of
plasma protein binding (%PPB) of all six 2,3-dihydro-1H-1,5-
benzodiazepin-2-ones were assessed (Table 2). The previously
reported study performed by Tavares et al., of ten successful
imaging agents established the limits of each of these parameters
(log P < 4, Pm < 0.5, Km < 250, %PPB < 95%). Based on these
criteria, compounds 31 and 4 were found to have the best physi-
ochemical properties for further development. While the log P
values were just above the acceptable limit, Tavares et al., do
emphasise that log P is the weakest predictor of brain penetration.
More importantly, 31 and 4 gave excellent results for permeability,
membrane partition coeﬃcient and percentage of plasma protein
binding. Based on these results, 31 and 4 have been selected for
further development as molecular imaging agents for mGluR2.
Having established 2,3-dihydro-1H-1,5-benzodiazepin-2-ones
31 and 4 as potential imaging agents for mGluR2, it was impor-
tant to identify synthetic approaches for the radiolabelling of
these compounds. Radioiodination of compound 31 for SPECTMed. Chem. Commun., 2013, 4, 1118–1123 | 1121
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View Article Onlineimaging could be envisaged using the standard two-step stan-
nylation/oxidative iodo-destannylation already utilised for the
synthesis of compounds 2, 3 and 6 (Scheme 5). Thus, application
of this approach with 31 as the precursor and using [123I]- or
[125I]-sodium iodide would allow introduction of radioiodine at
the nal step. While there are toxicity issues in using organotin
compounds for the preparation of neurological SPECT imaging
agents, the radioiodinated products are generally puried to a
high level using HPLC.
The synthesis described for the preparation of compound 4
(Schemes 2 and 4) where the methyl group is introduced at an
early stage would not be amenable to [11C]-labelling of this
compound. Therefore, a synthetic route was developed to a
suitable precursor that would allow [11C]-methylation as the nal
step (Scheme 6). Previously synthesised chloroaniline 13 was
subjected to a nucleophilic aromatic substitution reaction with
benzyl alcohol which gave 36 in 60% yield. Boc-protection of 36
using the two-step approach followed by reduction of the nitro-
groupwith tin(II) chloride dihydrate gave selectively protected 1,2-
diaminobenzene 38 in excellent overall yield. Coupling of 38with
b-keto ester 30 and TFA mediated cyclisation gave 2,3-dihydro-
1H-1,5-benzodiazepin-2-one 39 in 65% yield over the two steps.
Finally, removal of the benzyl protecting group using boron tri-
bromide gave phenol 40 in 81% yield. This seven-step approachScheme 6 Reagents and conditions: (a) BnOH, KOH, n-Bu4NBr, 60 C, 60%; (b)
Boc2O (2.2 eq.), Et3N, DMAP (0.2 eq.), CH2Cl2, 98%; (c) TFA, CH2Cl2, 97%; (d)
SnCl2$2H2O, EtOH, 70 C, 98%; (e) 30, D, toluene; (f) TFA, CH2Cl2, 65% yields over
two steps; (g) BBr3, CH2Cl2, 81%.
1122 | Med. Chem. Commun., 2013, 4, 1118–1123allows rapid access to a precursor which on alkylation with [11C]-
methyl iodide would give the radiolabelled version of compound
4 for PET imaging. Alkylation with other groups would also result
in the late-stage preparation of further non-labelled analogues in
this series for biological testing.Conclusions
In summary, six novel 2,3-dihydro-1H-1,5-benzodiazepin-2-ones
bearing sites for radiolabelling have been successfully prepared
using a two-stage convergent approach involving the coupling
and cyclisation of a range of 1,2-diaminobenzenes with an
imidazole derived b-keto ester. Biological evaluation of these
compounds against membrane expressing human mGluR2
using a functional [35S]GTPgS assay showed these compounds
to have excellent aﬃnity as non-competitive antagonists for
mGluR2. Evaluation of the key physiochemical properties
required for a successful neurological imaging agent using
established HPLC methods identied compounds 31 and 4 as
potential SPECT and PET tracers for mGluR2, respectively.
Work is currently underway to establish a radiosynthesis of
these compounds from precursors 31 and 40 and evaluate their
mGluR selectivity and biodistribution in vivo.Acknowledgements
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